Ihnat Daniel M, Mills Joseph L
Department of Vascular and Endovascular Surgery, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA.
J Am Podiatr Med Assoc. 2010 Sep-Oct;100(5):424-8. doi: 10.7547/1000424.
Endovascular therapy has increasingly become the initial clinical option for the treatment of lower-extremity peripheral arterial occlusive disease not only for patients with claudication but also for those with critical limb ischemia. Despite this major clinical practice paradigm shift, the outcomes of endovascular therapy for peripheral arterial disease are difficult to evaluate and compare with established surgical benchmarks because of the lack of prospective randomized trials, incomplete characterization of indications for intervention, mixing of arterial segments and extent of disease treated, the multiplicity of endovascular therapy techniques used, the exclusion of early treatment failures, crossover to open bypass during follow-up, and the frequent lack of intermediate and long-term patency and limb salvage rates in life-table format. These data limitations are especially problematic when one tries to assess the outcomes of endovascular therapy in patients with diabetes. The purpose of the present article is to succinctly review and objectively analyze available data regarding the results of endovascular therapy in patients with diabetes.
血管内治疗不仅已日益成为治疗下肢外周动脉闭塞性疾病(包括间歇性跛行患者和严重肢体缺血患者)的初始临床选择。尽管出现了这一重大的临床实践模式转变,但由于缺乏前瞻性随机试验、干预指征的特征描述不完整、治疗的动脉节段和疾病范围的混合、所使用的血管内治疗技术的多样性、早期治疗失败病例的排除、随访期间转为开放旁路手术以及生命表格式中经常缺乏中期和长期通畅率及肢体挽救率,外周动脉疾病血管内治疗的结果难以评估,也难以与既定的手术基准进行比较。当试图评估糖尿病患者血管内治疗的结果时,这些数据限制尤其成问题。本文的目的是简要回顾并客观分析有关糖尿病患者血管内治疗结果的现有数据。